HPLC analysis of the antidepressant trazodone and its main metabolite m-CPP in human plasma

Journal of Pharmaceutical and Biomedical Analysis

Volumn 47, Issue 4-5, 2008, Pages 882-887

  Mercolini, Laura ^a   Colliva, Carolina ^a   Amore, Mario ^b   Fanali, Salvatore ^c   Raggi, Maria Augusta ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c CNR   (Italy)

Author keywords

HPLC; Human plasma; m CPP; Solid phase extraction; Therapeutic drug monitoring; Trazodone

Indexed keywords

3 (1 CLOROPHENYL)PIPERAZINE; ACETONITRILE; ANTIDEPRESSANT AGENT; BUFFER; DRUG METABOLITE; LOXAPINE; PHOSPHATE; SEROTONIN ANTAGONIST; TRAZODONE; TRIETHYLAMINE;

ACCURACY; ACIDITY; ADVERSE OUTCOME; AQUEOUS SOLUTION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID LIQUID EXTRACTION; PRIORITY JOURNAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; SEPARATION TECHNIQUE; SOLID PHASE EXTRACTION; STANDARD; ULTRAVIOLET SPECTROSCOPY;

ACETONITRILES; ANTIDEPRESSIVE AGENTS; BUFFERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSION; DRUG STABILITY; ETHYLAMINES; FEASIBILITY STUDIES; FREEZING; HUMANS; HYDROGEN-ION CONCENTRATION; MOLECULAR STRUCTURE; PHOSPHATES; PIPERAZINES; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETRY, ULTRAVIOLET; TIME FACTORS; TRAZODONE; WATER;

EID: 44749090451     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2008.02.028     Document Type: Article

References (31)

1. Marek G.J., McDougle C.J., Price L.H., and Seiden L.S. Psychopharmacology 109 (1992) 2-11
2. Maes M., Vandoolaeghe E., and Desnyder R. J. Affect. Disorders 41 (1996) 201-210
3. Bertschy G., Ragama-Pardos E., Muscionico M., Ait-Ameur A., Roth L., Osiek C., and Ferrero F. Pharm. Res. 51 (2005) 79-84
4. FDA Approved Drug Products, available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (last accessed on January 15, 2008).
5. Rotzinger S., Fang J., and Baker G.B. Drug Metab. Dispos. 26 (1998) 572-575
6. Samad N., Haleem M.A., and Haleem D.J. J. Chem. Soc. Pakistan 28 (2006) 605-610
7. Vatassery G.T., Holden L.A., Hazel D.K., and Dysken M.W. Clin. Biochem. 30 (1997) 149-153
8. Yasui N., Otani K., Kaneko S., Ohkubo T., Osanai T., Ishida M., Mihara K., Kondo T., Sugawara K., and Fukushima Y.N. Ther. Drug Monit. 17 (1995) 333-335
9. In: Sweetman S.C. (Ed). Martindale the Complete Drug Reference. 34th edition (2004), Pharmaceutical Press, London 319
10. Tancer M.E., and Johanson C.E. Drug Alcohol Depen. 65 (2001) 97-101
11. Caballero J., and Nahata M.C. Am. J. Health-Syst. Pharm. 62 (2005) 864-867
12. Valuck R.J., Libby A.M., Sills M.R., Giese A.A., and Allen R.R. CNS Drugs 18 (2004) 1119-1132
13. Antidepressant use in children, adolescents, and adults: revisions to product labeling. Available from: http://www.fda.gov/cder/drug/antidepressants/antidepressants_label_change_2007.pdf (last accessed on January 15, 2008).
14. Mitchell P.B. Brit. J. Clin. Pharmacol. 52 (2001) 45-54
15. Raggi M.A. Curr. Med. Chem. 9 (2002) 1397-1409
16. Raggi M.A., Mandrioli R., Pucci V., and Sabbioni C. Curr. Med. Chem. 11 (2004) 279-296
17. Albers L.J., and Ozdemir V. Curr. Med. Chem. 11 (2004) 297-312
18. Capuano B., Crosby I.T., and Lloyd E.J. Curr. Med. Chem 9 (2002) 521-548
19. Belvedere G., Frigerio A., and Pantarotto C. J. Chromatogr. 112 (1975) 631-636
20. Gammans R.E., Kerns E.H., Bullen W.W., Covington R.R., and Russell J.W. J. Chromatogr. 339 (1985) 303-312
21. Caccia S., Ballabio M., Fanelli R., Guiso G., and Zanini M.G. J. Chromatogr. 210 (1981) 311-318
22. Kang X., Pan C., Xu Q., Yao Y., Wang Y., Qi D., and Gu Z. Anal. Chim. Acta 587 (2007) 75-81
23. Ohkubo T., Osanai T., Sugawara K., Ishida M., Otani K., Mihara K., and Yasui N. J. Pharm. Pharmacol. 47 (1995) 340-344
24. Wong S.H.Y. Methodol. Anal. Toxicol. 3 (1985) 189-193
25. Carda-Broch S., Gil-Agustí M.T., Monferrer-Pons L., and Esteve-Romero J.S. J. Chromatogr. A 1156 (2007) 254-258
26. de Castro A., Fernandez M.M.R., Laloup M., Samyn N., De Boeck G., Wood M., Maes V., and Lopez-Rivadulla M. J. Chromatogr. A 1160 (2007) 3-12
27. Kirchherr H., and Kuehn-Velten W.N. J. Chromatogr. B 843 (2006) 100-113
28. Shinozuka T., Terada M., and Tanaka E. For. Sci. Int. 162 (2006) 108-112
29. ICH Harmonised tripartite guideline validation of analytical procedures: text and methodology Q2(R1). Parent Guideline dated October 27, 1994 (Complementary Guideline on Methodology dated 6 November 1996 incorporated in November 2005). Available from http://www.ich.org/LOB/media/MEDIA417.pdf (last accessed on January 15, 2008).
30. United States Pharmacopeia, 28th edition, United States Pharmacopeial Convention, Rockville, 2005, pp. 2748-2751.
31. U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Bioanalytical Method Validation, May 2001. Available from http://www.fda.gov/CDER/GUIDANCE/4252fnl.pdf (last accessed on January 15, 2008).